霍奇金淋巴瘤最新治疗进展：第53届美国血液学会年会深度报道  

Report on recent treatment of Hodgkin＇s lymphoma in the 53rd annual meeting of American Society of Hematology

作　　者：邹志建[1] 徐卫[1] 李建勇[1] 

机构地区：[1]南京医科大学第一附属医院江苏省人民医院血液科,210029

出　　处：《白血病．淋巴瘤》2012年第2期70-72,共3页Journal of Leukemia & Lymphoma

摘　　要：在近十年里，霍奇金淋巴瘤（HL）对大多数患者而言已成为可治愈的恶性肿瘤。目前的一线治疗通常采用ABVD方案化疗或联合其他药物和放疗。为了更好地控制疾病，ABVD方案一直受到强度更大的治疗如Stanford V和BEACOPP化疗方案的挑战。在第53届美国血液学会（ASH）年会报告中，ABVD方案作为治疗包括人类免疫缺陷病毒（HIV）感染者及老年HL患者的标准方案仍广为大家接受，但对一线临床医生来说，治疗复发难治HL还是一个具有挑战性的任务，大剂量化疗序贯自体造血干细胞移植（HDC／ASCT）对此类患者最为有益，同时用于这部分患者治疗的许多新药也在研发中。正电子发射计算机断层扫描（PET）能为接受化疗或移植前后的HL患者提供重要的预后信息，但在会议报道中对治疗后患者进行影像学的长期监测并不被推荐。Hodgkin＇s lymphoma （HL） is a highly curable malignancy for most patients during the recent decades. Frontline treatment is generally ABVD alone or in combination with other chemotherapy regimens or radiation. To achieve a higher control of disease, ABVD chemotherapy has been challenged by more intensive treatments, such as Stanford V and BEACOPP regimen. In the 53rd ASH annual meeting, ABVD is still widely accepted as standard regimen for HL, even in elderly people or patients with HIV infection. Relapsed or refractory HL is a challenging problem for clinician, and high dose chemotherapy followed by autologous stem cell transplantation （HDC/ASCT） is the preferred treatment for chemoresistant patients. Many novel treatment strategies were explored for these patients. Positron emission tomography （PET） scanning provides important prognostic information in patients with HL receiving chemotherapy or pre/posttransplant, but the utility of long term surveillance radiological studies is not recommended in the meeting.

关 键 词：霍奇金淋巴瘤 移植 美国血液学会年会 

分 类 号：R733.1[医药卫生—肿瘤]